Tuesday, Dec 17, 1985
South San Francisco, Calif. -- December 17, 1985 --Genentech, Inc. today reported that its Protropin® growth hormone has received orphan drug status for the treatment of growth hormone deficiency and Turner's Syndrome. This designation, under the Federal Food, Drug and Cosmetic Act, provides incentives for the development of drugs for diseases or disorders for which the potential patient population is under 200,000. Under the Act, Genentech is entitled to seven years exclusivity to market the drug for its approved indication.
Protropin growth hormone has been approved by the Food and Drug Administrationfor the treatment of growth hormone deficiency. Protropin is currently being tested in the treatment of Turner's Syndrome, a chromosomal disorder that affects female children. Genentech is a leading biotechnology company, focusing on the development, manufacture and marketing of pharmaceuticals produced by recombinant DNA technology.
# # #